{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:10:53Z","timestamp":1791040253078,"version":"4.1.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders that, for the most part, are associated with a very poor prognosis. The standard therapy for PTCLs is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a comparable CHOP-like regimen that incorporates anthracyclines. With the exception of anaplastic lymphoma kinase\u2013positive anaplastic large cell lymphoma (ALK+ ALCL), the cure rate for PTCLs with CHOP is low, and limited evidence suggests that anthracyclines do not improve the prognosis. However, there is no compelling evidence that any other regimen or approach is superior. It remains challenging to compare alternative therapies or treatment strategies with CHOP because the majority of data are retrospective and include diverse patient populations. Recently, prospective studies have been initiated exclusively for PTCL, and in some, select histologic subtypes are evaluated in an effort to remove heterogeneity. Encouragingly, there have been several new therapies emerging with activity in PTCLs and exciting novel combinations under consideration that will hopefully move the field forward and improve outcome in this challenging group of diseases.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.515","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"515-524","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Therapies for Peripheral T-Cell Lymphomas"],"prefix":"10.1182","volume":"2011","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[{"name":"BC Cancer Agency, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2019111717424374100_B1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111717424374100_B2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111717424374100_B3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111717424374100_B4","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111717424374100_B5","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2019111717424374100_B6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111717424374100_B7","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111717424374100_B8","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood.V116.21.2795.2795","article-title":"Multicenter phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers [Abstract]","volume":"116","author":"Niitsu","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111717424374100_B9","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111717424374100_B10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"issue":"23","key":"2019111717424374100_B11","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111717424374100_B12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2019111717424374100_B13","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111717424374100_B14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","article-title":"A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"51","author":"Weidmann","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111717424374100_B15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2000.n.009","article-title":"DAB389IL-2 (ONTAK): A novel fusion toxin therapy for lymphoma","volume":"1","author":"Foss","year":"2000","journal-title":"Clin Lymphoma"},{"issue":"20","key":"2019111717424374100_B16","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.2004.03.071","article-title":"Phase II study of denileukin diftitox for relapsed\/refractory B-Cell non-Hodgkin's lymphoma","volume":"22","author":"Dang","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15s","key":"2019111717424374100_B17","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/jco.2010.28.15_suppl.8045","article-title":"Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial [Abstract]","volume":"28","author":"Foss","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111717424374100_B18","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood.V114.22.1671.1671","article-title":"Cardiac toxcity associated with the anti-VEGF monoclonal antibody Bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T-cell lymphoma (PTCL): The ECOG 2404 trial [Abstract]","volume":"114","author":"Advani","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111717424374100_B19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"15S","key":"2019111717424374100_B20","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1200\/jco.2009.27.15_suppl.8554","article-title":"A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05\u20131T trial [Abstract]","volume":"27","author":"Delmer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111717424374100_B21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111717424374100_B22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"2019111717424374100_B23","first-page":"111","article-title":"Phase II trial of cisplatin plus etoposide plus gemcitabine plus solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350) [Abstract]","volume":"22","author":"Mahadevan","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"2019111717424374100_B24","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood.V116.21.2829.2829","article-title":"Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell\/NK lymphomas: a phase II trial [Abstract]","volume":"116","author":"Corazzelli","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111717424374100_B25","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma","volume":"103","author":"Escal\u00f3n","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"2019111717424374100_B26","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"issue":"12","key":"2019111717424374100_B27","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"key":"2019111717424374100_B28","first-page":"437","article-title":"Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)\u2013overall and subtype-specific results of a phase II study from Nordic lymphoma group [Abstract]","volume":"94","author":"d'Amore","year":"2009","journal-title":"Haematologica"},{"issue":"21","key":"2019111717424374100_B29","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/blood.V116.21.3566.3566","article-title":"Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and autologous stem cell transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01) [Abstract]","volume":"116","author":"Relander","year":"2010","journal-title":"Blood"},{"key":"2019111717424374100_B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/320624","article-title":"Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas","volume":"2010","author":"Reimer","year":"2010","journal-title":"Adv Hematol"},{"issue":"14","key":"2019111717424374100_B31","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111717424374100_B32","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111717424374100_B33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"issue":"35","key":"2019111717424374100_B34","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"33","key":"2019111717424374100_B35","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111717424374100_B36","unstructured":"National Comprehensive Cancer Network Extranodal NK\/T-cell lymphoma, nasal type. NCCN Guidelines Version 3.2011 Accessed May 15, 2011 Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf"},{"issue":"11","key":"2019111717424374100_B37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood.V108.11.292.292","article-title":"Clinical and pathological differences between nasal and nasal-type NK\/T Cell lymphomas: a summary of 136 cases from the International T Cell Lymphoma (ITCL) Project [Abstract]","volume":"108","author":"Au","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111717424374100_B38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdn542","article-title":"L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature","volume":"20","author":"Jaccard","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111717424374100_B39","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111717424374100_B40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/10428190601126941","article-title":"Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma","volume":"48","author":"Konuma","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2019111717424374100_B41","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111717424374100_B42","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111717424374100_B43","first-page":"126","article-title":"Preliminary results from an open label multi-center, phase II study of bendamustine in relapsed or refractory T-cell lymphoma from the French GOELAMS group: The Bently trial [Abstract]","volume":"22","author":"Damaj","year":"2011","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111717424374100_B44","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"issue":"21","key":"2019111717424374100_B45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood.V116.21.114.114","article-title":"Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy [Abstract]","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111717424374100_B46","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase II trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2019111717424374100_B47","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood.V114.22.920.920","article-title":"Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [Abstract]","volume":"114","author":"Pohlman","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111717424374100_B48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111717424374100_B49","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111717424374100_B50","first-page":"125a","article-title":"Durable remissions with SGN-et (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [Abstract]","volume":"22","author":"Shustov","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111717424374100_B51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"d'Amore","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111717424374100_B52","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V112.11.2005.2005","article-title":"Phase I results of combination gemcitabine and bortezomib (Velcade(R)) for relapsed\/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-Cell NHL (B-NHL) [Abstract]","volume":"112","author":"Evens","year":"2008","journal-title":"Blood"},{"key":"2019111717424374100_B53","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminhematol.2010.01.014","article-title":"Novel agents in development for peripheral T-cell lymphoma","volume":"47","author":"O'Connor","year":"2010","journal-title":"Semin Hematol"},{"issue":"19","key":"2019111717424374100_B54","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"2019111717424374100_B55","first-page":"152","article-title":"Multicenter phase II trial of MLN8237, an investigational inhibitor of aurora A kinase (AAK) in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL) [Abstract]","volume":"22","author":"Friedberg","year":"2011","journal-title":"Ann Oncol"},{"key":"2019111717424374100_B56","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"International Agency for Research on Cancer","year":"2008"},{"issue":"21","key":"2019111717424374100_B57","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.V116.21.1791.1791","article-title":"The efficacy of bortezomib-CHOP In patients with advanced stage T or NK\/T cell lymphomas: the results of multicenter phase II study [Abstract]","volume":"116","author":"Kim","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111717424374100_B58","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"8","key":"2019111717424374100_B59","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111717424374100_B60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/515\/1494913\/bep00111000515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/515\/1494913\/bep00111000515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T05:01:35Z","timestamp":1639890095000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/515\/96995\/Therapies-for-Peripheral-TCell-Lymphomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.515","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}